Finally, we demonstrate that MST1/2 inhibition can overcome tamoxifen resistance conferred by frequently occurring point mutations in ERα, suggesting that targeting the Hippo pathway could be a potential strategy to overcome endocrine therapy resistance in breast cancer patients. The gene discussed is ESR1; the disease is breast carcinoma.